Design Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview

Design Therapeutics

15/03/2024 20:56

* Design Therapeutics Inc  DSGN.OQ   DSGN.O  is expected
to show
no change in quarterly revenue when it reports  results on March
19 for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Design Therapeutics Inc
is for
a loss of 31 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Design
Therapeutics Inc is $4.50​, above​ its last closing price
of $2.48. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.38       -0.41      -0.28     Beat    31.5
 Jun. 30 2023  -0.39       -0.40      -0.36     Beat    9.4
 Mar. 31 2023  -0.36       -0.36      -0.35     Beat    2.6​
 Dec. 31 2022  -0.38       -0.34      -0.31     Beat    9.9
 ​​Sep.        -0.29       -0.29      -0.32     Missed  -11.1
 30 2022                                                
 Jun. 30 2022  -0.25       -0.25      -0.27     Missed  -8​
 Mar. 31 2022  -0.22       -0.22      -0.24     Missed  -9.1
 Dec. 31 2021  -0.25       -0.23      -0.20     Beat    11.8
 This summary was machine generated March 15 at 20:56 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)